ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded at StockNews.com

ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Saturday.

ACAD has been the subject of a number of other research reports. Guggenheim cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Morgan Stanley reissued an “equal weight” rating and issued a $20.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft started coverage on ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They set a “hold” rating and a $22.00 target price on the stock. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $24.00.

ACADIA Pharmaceuticals Stock Performance

ACADIA Pharmaceuticals stock opened at $17.56 on Friday. The firm has a market cap of $2.92 billion, a price-to-earnings ratio of 22.51 and a beta of 0.37. The firm has a 50 day moving average price of $18.49 and a two-hundred day moving average price of $16.91. ACADIA Pharmaceuticals has a 52-week low of $14.15 and a 52-week high of $24.27.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now directly owns 17,595 shares of the company’s stock, valued at approximately $320,756.85. This represents a 21.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 6,167 shares of company stock valued at $114,583 in the last 90 days. 28.30% of the stock is currently owned by company insiders.

Institutional Trading of ACADIA Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC grew its position in shares of ACADIA Pharmaceuticals by 380.3% during the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after purchasing an additional 1,966,607 shares in the last quarter. Barclays PLC grew its position in ACADIA Pharmaceuticals by 126.2% during the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock worth $4,269,000 after buying an additional 154,854 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in ACADIA Pharmaceuticals in the 3rd quarter worth about $483,000. Burney Co. purchased a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at about $6,953,000. Finally, BNP Paribas Financial Markets boosted its position in shares of ACADIA Pharmaceuticals by 259.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company’s stock valued at $3,439,000 after acquiring an additional 161,331 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.